Literature DB >> 25810396

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Erola Ainsua-Enrich1, Eva Serrano-Candelas1, Damiana Álvarez-Errico1, César Picado2, Joan Sayós3, Juan Rivera4, Margarita Martín5.   

Abstract

SH3-binding protein 2 (3BP2) is a cytoplasmic adaptor protein that acts as a positive regulator in mast cell FcεRI-dependent signaling. The KIT receptor whose ligand is the stem cell factor is necessary for mast cell development, proliferation, and survival as well as for optimal IgE-dependent signal. Activating mutations in KIT have been associated with several diseases including mastocytosis. In the present work, we found that 3BP2 silencing impairs KIT signaling pathways, thus affecting phosphoinositide 3-kinase and MAPK pathways in human mast cells (huMCs) from HMC-1, LAD2 (huMC lines), and CD34(+)-derived mast cells. Unexpectedly, silencing of 3BP2 reduces KIT expression in normal huMCs as well as in HMC-1 cells where KIT is mutated, thus increasing cellular apoptosis and caspase-3/7 activity. 3BP2 silencing reduces KIT transcription expression levels. Interestingly, 3BP2 silencing decreased microphthalmia-associated transcription factor (MITF) expression, a transcription factor involved in KIT expression. Reconstitution of 3BP2 in knockdown cells leads to reversal of KIT expression as well as survival phenotype. Accordingly MITF reconstitution enhances KIT expression levels in 3BP2-silenced cells. Moreover, downregulation of KIT expression by miRNA-221 overexpression or the proteasome inhibitor bortezomib also reduced 3BP2 and MITF expression. Furthermore, KIT tyrosine activity inhibition reduced 3BP2 and MITF expression, demonstrating again a tight and reciprocal relationship between these molecules. Taken together, our results show that 3BP2 regulates huMC survival and participates in KIT-mediated signal transduction by directly controlling KIT receptor expression, suggesting its potential as a therapeutic target in mast cell-mediated inflammatory diseases and deregulated KIT disorders.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25810396      PMCID: PMC4402263          DOI: 10.4049/jimmunol.1402887

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Determination of protein phosphorylation in Fc epsilon RI-activated human mast cells by immunoblot analysis requires protein extraction under denaturing conditions.

Authors:  Christine Tkaczyk; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  J Immunol Methods       Date:  2002-10-15       Impact factor: 2.303

3.  Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.

Authors:  Michelle J Frost; Petranel T Ferrao; Timothy P Hughes; Leonie K Ashman
Journal:  Mol Cancer Ther       Date:  2002-10       Impact factor: 6.261

4.  Establishment of an immature mast cell line from a patient with mast cell leukemia.

Authors:  J H Butterfield; D Weiler; G Dewald; G J Gleich
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

5.  Identification of a ten-amino acid proline-rich SH3 binding site.

Authors:  R Ren; B J Mayer; P Cicchetti; D Baltimore
Journal:  Science       Date:  1993-02-19       Impact factor: 47.728

6.  Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling.

Authors:  Kim C Mansky; Uma Sankar; Jiahuai Han; Michael C Ostrowski
Journal:  J Biol Chem       Date:  2002-01-15       Impact factor: 5.157

7.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 8.  Mitf and Tfe3: members of a b-HLH-ZIP transcription factor family essential for osteoclast development and function.

Authors:  Christine L Hershey; David E Fisher
Journal:  Bone       Date:  2004-04       Impact factor: 4.398

9.  Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells.

Authors:  Thomas R Hundley; Alasdair M Gilfillan; Christine Tkaczyk; Marcus V Andrade; Dean D Metcalfe; Michael A Beaven
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

10.  Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI.

Authors:  Arnold S Kirshenbaum; Cem Akin; Yalin Wu; Menachem Rottem; Julie P Goff; Michael A Beaven; V Koneti Rao; Dean D Metcalfe
Journal:  Leuk Res       Date:  2003-08       Impact factor: 3.156

View more
  10 in total

1.  Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.

Authors:  Mizuho Kittaka; Tetsuya Yoshimoto; Collin Schlosser; Robert Rottapel; Mikihito Kajiya; Hidemi Kurihara; Ernst J Reichenberger; Yasuyoshi Ueki
Journal:  J Bone Miner Res       Date:  2019-10-24       Impact factor: 6.741

2.  KIT signaling is dispensable for human mast cell progenitor development.

Authors:  Joakim S Dahlin; Maria Ekoff; Jennine Grootens; Liza Löf; Rose-Marie Amini; Hans Hagberg; Johanna S Ungerstedt; Ulla Olsson-Strömberg; Gunnar Nilsson
Journal:  Blood       Date:  2017-08-08       Impact factor: 22.113

3.  The microphthalmia-associated transcription factor is involved in gastrointestinal stromal tumor growth.

Authors:  Proaño-Pérez Elizabeth; Serrano-Candelas Eva; García-Valverde Alfonso; Rosell Jordi; Gómez-Peregrina David; Navinés-Ferrer Arnau; Guerrero Mario; Serrano César; Martín Margarita
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

Review 4.  KIT as a master regulator of the mast cell lineage.

Authors:  Mindy Tsai; Peter Valent; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2022-04-22       Impact factor: 14.290

5.  Development of a Soluble KIT Electrochemical Aptasensor for Cancer Theranostics.

Authors:  Saeromi Chung; Jason K Sicklick; Partha Ray; Drew A Hall
Journal:  ACS Sens       Date:  2021-05-19       Impact factor: 9.618

6.  Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.

Authors:  Eva Serrano-Candelas; Erola Ainsua-Enrich; Arnau Navinés-Ferrer; Paulo Rodrigues; Alfonso García-Valverde; Sarah Bazzocco; Irati Macaya; Joaquín Arribas; César Serrano; Joan Sayós; Diego Arango; Margarita Martin
Journal:  Mol Oncol       Date:  2018-06-30       Impact factor: 6.603

7.  Mast cells participate in regulation of lung-gut axis during Staphylococcus aureus pneumonia.

Authors:  Chao Liu; Liping Yang; Yu Han; Wei Ouyang; Wei Yin; Feng Xu
Journal:  Cell Prolif       Date:  2019-02-07       Impact factor: 6.831

8.  Myo1f, an Unconventional Long-Tailed Myosin, Is a New Partner for the Adaptor 3BP2 Involved in Mast Cell Migration.

Authors:  Arnau Navinés-Ferrer; Erola Ainsua-Enrich; Eva Serrano-Candelas; Joan Sayós; Margarita Martin
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 9.  Long-Tailed Unconventional Class I Myosins in Health and Disease.

Authors:  A Navinés-Ferrer; M Martín
Journal:  Int J Mol Sci       Date:  2020-04-07       Impact factor: 5.923

Review 10.  The underestimated role of the microphthalmia-associated transcription factor (MiTF) in normal and pathological haematopoiesis.

Authors:  Alessia Oppezzo; Filippo Rosselli
Journal:  Cell Biosci       Date:  2021-01-13       Impact factor: 7.133

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.